Duration of SARS-CoV-2 mRNA vaccine persistence and factors associated with cardiac involvement in recently vaccinated patients
Abstract At the start of the COVID-19 pandemic, the BNT162b2 (BioNTech-Pfizer) and mRNA-1273 (Moderna) mRNA vaccines were expediently designed and mass produced. Both vaccines produce the full-length SARS-CoV-2 spike protein for gain of immunity and have greatly reduced mortality and morbidity from...
Main Authors: | Aram J. Krauson, Faye Victoria C. Casimero, Zakir Siddiquee, James R. Stone |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2023-09-01
|
Series: | npj Vaccines |
Online Access: | https://doi.org/10.1038/s41541-023-00742-7 |
Similar Items
-
Recent Updates on mRNA Vaccines
by: Emily Sydow, et al.
Published: (2022-07-01) -
Association between sleep duration and antibody acquisition after mRNA vaccination against SARS-CoV-2
by: Muneto Izuhara, et al.
Published: (2023-12-01) -
Predictors of persistent symptoms after mRNA SARS-CoV-2 vaccine-related myocarditis (myovacc registry)
by: Daniel Schroth, et al.
Published: (2023-06-01) -
Persistent memory despite rapid contraction of circulating T Cell responses to SARS-CoV-2 mRNA vaccination
by: Ellie Taus, et al.
Published: (2023-02-01) -
Recent progress in mRNA cancer vaccines
by: Ruhui Yao, et al.
Published: (2024-12-01)